Clinical Trial

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Study acronym: InMIND
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Protocol Amendment History 41 amendments
This ClinicalTrials.gov record has been amended 41 times since 2020-12-17; most recent amendment 2025-12-04.
Status change: Recruiting → Active, Not Recruiting 2023-08-15
Status change: Not Yet Recruiting → Recruiting 2021-03-02
Trial Details
NCT Number NCT04680052
Lead Sponsor Incyte Corporation
Conditions Follicular Lymphoma, Marginal Zone Lymphoma
Enrollment 654 participants
Start Date 2021-04-15
Primary Completion 2024-02-23 (estimated)
Study Completion 2028-08-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-22